Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
Nucleoside Reverse Transcriptase Inhibitor
Azvudine is a potent nucleoside reverse transcriptase inhibitor (NRTI) with notable antiviral activity against HIV, HBV, and HCV. It exhibits strong inhibition of HIV-1 and HIV-2, with EC50 values ranging from 0.018 to 6.92 nM, and effectively targets NRTI-resistant strains. Additionally, Azvudine serves as a click chemistry reagent, featuring an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules or those with DBCO or BCN groups, making it suitable for advanced chemical biology applications. -
Reverse Transcriptase Inhibitor
FNC-TP is the intracellular active form of the nucleoside reverse transcriptase inhibitor (NRTI) FNC, targeting reverse transcriptase enzymes. This compound exhibits potent antiviral activity against HIV, HBV, and HCV. Additionally, FNC-TP serves as a versatile click chemistry reagent, featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne, DBCO, or BCN-containing molecules, facilitating advanced research applications in chemical biology. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate TEA is a potent reverse transcriptase inhibitor that functions by terminating the elongation of viral nucleic acids. It effectively inhibits the reverse transcriptase of HIV and HBV, thereby obstructing viral replication. Additionally, Lamivudine triphosphate TEA targets the RNA-dependent RNA polymerase (RdRp) of the NS5B subunit in HCV, and can be incorporated into the RNA by the RdRp of SARS-CoV-2, interrupting the synthesis and leading to a decrease in mutations in the viral genome. This makes it a critical reagent for research in antiviral therapies and viral replication studies. -
Reverse Transcriptase Inhibitor
Lamivudine salicylate is a nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against HIV reverse transcriptase 1/2 and hepatitis B virus reverse transcriptase. Its oral bioavailability and ability to penetrate the central nervous system make it a valuable compound for anti-viral research. Lamivudine salicylate is widely utilized in studies focused on the treatment and management of HIV and hepatitis B infections. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate is a potent reverse transcriptase inhibitor that serves as a phosphorylated form of the nucleoside analogue Lamivudine. It effectively disrupts the replication of HIV and HBV viruses through chain termination. Additionally, Lamivudine triphosphate inhibits the RNA-dependent RNA polymerase (RdRp) activity of the NS5B subunit in hepatitis C virus, and can be incorporated into nascent RNA by the SARS-CoV-2 RdRp, thereby preventing mutations in the SARS-CoV-2 RNA. This makes it a valuable reagent for research on viral replication mechanisms and antiviral drug development. -
Nucleoside Reverse Transcriptase Inhibitor
Metacavir is a potent nucleoside reverse transcriptase inhibitor primarily targeting the hepatitis B virus (HBV). This orally active compound exhibits significant antiviral activity, making it a valuable tool in the research of antiviral therapies and the development of treatments for HBV infections. Its specificity and efficacy in inhibiting reverse transcriptase contribute to its potential application in studying hepatitis B and related disorders. -
Reverse Transcriptase Inhibitor
5'-Azido-5'-deoxythymidine is a nucleoside analogue that functions as an inhibitor of reverse transcriptase. By mimicking natural nucleosides, it integrates into viral DNA during replication, thereby terminating chain elongation and effectively inhibiting viral propagation. This compound is valuable for research into retroviral infections, including AIDS, contributing to the understanding and treatment of these diseases. -
reverse transcriptase inhibitor
Depulfavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates exceptional antiviral activity with an IC50 of 1.1 nM against wild-type HIV-1 and maintains effectiveness (IC50 < 100 nM) against 92% of various NNRTI-resistant clinical isolates. This compound is valuable for research into HIV resistance mechanisms and the development of novel antiviral therapies. -
AMV Reverse Transcriptase Inhibitor
Limocrocin is an inhibitor of avian myeloid leukemia virus (AMV) reverse transcriptase. This compound, derived from Streptomyces limosus, exhibits significant inhibitory activity independent of variations in template-primer concentration, substrate, or carrier protein levels. However, its efficacy diminishes with increasing concentrations of AMV reverse transcriptase. Limocrocin serves as a valuable tool for research in antiviral treatment development. -
Non-nucleoside Reverse Transcriptase Inhibitor
(R)-Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts through non-competitive inhibition of the viral enzyme. It is selectively metabolized by CYP2B6 to form 8-hydroxyefavirenz, which highlights its potential as a probe for studying the CYP2B6 active site and its catalytic mechanisms. This compound serves as a valuable tool in the research of antiviral therapeutics and the pharmacokinetics of HIV treatment. -
Reverse Transcriptase Inhibitor
Trovirdine hydrochloride is an HIV reverse transcriptase inhibitor, acting as a non-nucleoside inhibitor (NNI) of the enzyme. It demonstrates significant biological activity against HIV replication, effectively achieving inhibition at nanomolar concentrations without cytotoxic effects in infected peripheral blood mononuclear cells. This compound serves as a valuable tool for research applications focused on understanding HIV therapeutics and developing more potent derivatives for enhancing antiviral strategies. -
Reverse Transcriptase Activator
TNK-6123 is a potent reverse transcriptase activator and an analogue of Emivirine, demonstrating enhanced efficacy against drug-resistant HIV variants. Specifically, TNK-6123 exhibits improved activity against the Lys103Asn mutant of reverse transcriptase. This compound is valuable for research in HIV resistance mechanisms and may contribute to the development of effective therapeutic strategies against resistant HIV strains. -
Reverse Transcriptase Inhibitor
Mniopetal E is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by interfering with the reverse transcription process, making it valuable for research in viral replication studies and the development of antiviral therapies. Its selective inhibition of reverse transcriptase may also provide insights into nucleic acid synthesis mechanisms in various biological systems. -
Reverse Transcriptase Inhibitor
Mniopetal B is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by interfering with the reverse transcription process, which is critical for the replication of retroviruses. Its mechanism makes Mniopetal B suitable for research applications focused on virology, HIV studies, and the development of antiviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal D is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by blocking the reverse transcription process, which is essential in the life cycle of retroviruses. Mniopetal D is utilized in research applications focused on antiviral drug development and understanding retroviral replication mechanisms. -
Reverse Transcriptase Inhibitor
Mniopetal F is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. It effectively disrupts the replication cycle of retroviruses by hindering the reverse transcription process, making it a valuable tool in antiviral research. Mniopetal F can be utilized in studies focused on understanding viral mechanisms and developing therapeutic strategies against retroviral infections. -
Reverse Transcriptase Inhibitor
NNRT-IN-5 is a non-nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. This compound functions by binding to the reverse transcriptase enzyme, disrupting the viral replication process. NNRT-IN-5 is primarily utilized in research to explore HIV mechanisms and develop novel therapeutic strategies targeting reverse transcriptase. -
Reverse Transcriptase Inhibitor
Mniopetal C is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by disrupting the reverse transcription process, making it valuable for research in molecular biology and virology. Mniopetal C can be utilized in studies focused on retroviral infections and the development of antiretroviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal A is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound has demonstrated significant ability to impede the reverse transcription process, making it a valuable tool in research focused on retroviral infections and related mechanisms. Its application extends to studies investigating viral replication, cellular responses to viral entry, and therapeutic developments targeting reverse transcription pathways. -
Nucleotide Reverse Transcriptase Inhibitor
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections. -
Reverse transcriptase inhibitor
Didanosine is a reverse transcriptase inhibitor, effective against HIV and used in combination with other antiretroviral drug therapy as part of highly active antiretroviral therapy (HAART). -
NRT inhibitor
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection. -
HIV reverse transcriptase inhibitor
Tenofovir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. -
nucleoside analogue reverse transcriptase inhibitor
Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection. -
HIV Reverse Transcriptase Inhibitor
β-Rubromycin is a selective inhibitor of HIV-1 reverse transcriptase, exhibiting a Ki of 0.27 μM. Additionally, it demonstrates potent telomerase inhibition with an IC50 of 3 μM. β-Rubromycin effectively inhibits the proliferation of K-562 and HeLa cell lines, showing IC50 values of 19.5 µM and 22.7 µM, respectively, making it a valuable tool for research in HIV and telomerase-related studies. -
Reverse Transcriptase Inhibitor
Abacavir hydrochloride is a competitive, orally active nucleoside reverse transcriptase inhibitor primarily targeting HIV replication. This compound demonstrates significant anti-HIV activity and has been shown to exhibit anticancer effects in prostate cancer cell lines. Furthermore, Abacavir hydrochloride has the ability to cross the blood-brain barrier and suppress telomerase activity, making it a valuable reagent for research in virology and cancer biology. -
Reverse Transcriptase Inhibitor
Abacavir monosulfate is a competitive, orally active nucleoside reverse transcriptase inhibitor targeting HIV replication. It demonstrates significant antiviral activity against HIV and exhibits anticancer properties in prostate cancer cell lines. Additionally, Abacavir monosulfate is capable of crossing the blood-brain barrier and effectively suppresses telomerase activity, making it a valuable tool for research in virology and oncology. -
Nucleoside Reverse Transcriptase Inhibitor
Stavudine is an orally active nucleoside reverse transcriptase inhibitor (NRTI) that selectively targets HIV-1 and HIV-2. In addition to its antiviral properties, Stavudine inhibits mitochondrial DNA replication and has been shown to reduce NLRP3 inflammasome activation while modulating Amyloid-β autophagy. Furthermore, Stavudine is associated with the induction of apoptosis, making it a valuable tool for research in HIV treatment and cellular apoptosis mechanisms. -
NNRT inhibitor
MK-1439 is a non-nucleoside reverse transcriptase inhibitor -
HIV reverse transcriptase inhibitor
Dapivirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) -
NNRT inhibitor
Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. -
NNRT inhibitor
Delavirdine is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). -
Transcriptase inhibitor
Abacavir sulfate is a nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS. -
NNRT inhibitor
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. -
NNRT inhibitor
Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. -
NRT inhibitor
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI). -
Purinergic P2 receptor antagonist
Pyridoxyl phosphate is a purinergic P2 receptor antagonist potentially for the treatment of tardive dyskinesia -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
nucleotide reverse transcriptase inhibitor
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. - (Z)-9-Propenyladenine is a mutagenic impurity in tenofovir disoproxil fumarate. Tenofovir is an antiretroviral drug known as nucleotide analogue reverse transcriptase (NtART) inhibitor, which blocks reverse transcriptase, a crucial virus enzyme in HIV-1 and HBV.
-
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
NNRT inhibitor
Elsulfavirine is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication.
